BioCentury | Jul 14, 2017
Strategy

Back to Ipsen’s roots

...included two hemophilia products being developed by partner Inspiration Biopharmaceuticals Inc. and prostate cancer therapy tasquinimod...
...are going to have to take those risks.” David Meek, Ipsen The second failure was tasquinimod...
...to be highly active between 2011 and the present. But Lebeaut said the hemophilia and tasquinimod...
BioCentury | Jun 7, 2017
Distillery Therapeutics

Cardiovascular; hematology

...treat Crohn's disease and Huntington's disease (HD). Active Biotech and Ipsen Group have TASQ tasquinimod (ABR-215050...
BioCentury | Nov 9, 2015
Clinical News

Tasquinimod: Phase III final data

...SSE:ACTI), Lund, Sweden Ipsen Group (Euronext:IPN; Pink:IPSEY), Boulogne-Billancourt, France Product: Tasquinimod ( TASQ ) ( ABR-215050...
...patients with metastatic CRPC who had not received chemotherapy showed that once-daily 0.25-1 mg oral tasquinimod...
...of tasquinimod in patients with prostate cancer after top-line data from the trial showed that tasquinimod...
BioCentury | Jul 27, 2015
Company News

Active Biotech cancer news

...37 (66%) to 19 employees after announcing in April that it would discontinue development of tasquinimod...
BioCentury | Jul 13, 2015
Finance

Mid-cap hot streak

...Company Setback Active Biotech (SSE:ACTI) / Ipsen Group (Euronext:IPN; Pink:IPSEY) Partners say they will discontinue tasquinimod...
...Pfizer Inc. (NYSE:PFE) CompanySetbackActive Biotech (SSE:ACTI) / Ipsen Group (Euronext:IPN; Pink:IPSEY)Partners say they will discontinue tasquinimod...
BioCentury | Apr 20, 2015
Clinical News

Tasquinimod: Development discontinued

...progressed after standard therapies. Ipsen and Active Biotech partnered in 2011 to co-develop and commercialize tasquinimod...
...SSE:ACTI), Lund, Sweden Ipsen Group (Euronext:IPN; Pink:IPSEY), Boulogne-Billancourt, France Product: Tasquinimod ( TASQ ) ( ABR-215050...
...1 mg oral tasquinimod did not improve OS vs. placebo (HR=1.09, 95% CI: 0.94, 1.28). Tasquinimod...
BioCentury | Apr 17, 2015
Clinical News

Active Biotech, Ipsen discontinue tasquinimod in mCRPC

...partner Ipsen Group (Euronext:IPN) said they would discontinue development of tasquinimod to treat prostate cancer. Tasquinimod...
...Phase II trial to treat four other cancer types do not support continued development of tasquinimod...
BioCentury | Nov 10, 2014
Clinical News

Tasquinimod: Preliminary Phase II data

...trial in patients with advanced cancers that progressed after standard therapies showed that once-daily oral tasquinimod...
...ovarian cancer cohort. In 38 renal cell carcinoma (RCC) patients pretreated with a VEGF inhibitor, tasquinimod...
...SSE:ACTI), Lund, Sweden Ipsen Group (Euronext:IPN; Pink:IPSEY), Boulogne-Billancourt, France Product: Tasquinimod ( TASQ ) ( ABR-215050...
BioCentury | Oct 6, 2014
Finance

4Q14 Financial Markets Preview: Commercial race in HCV

...valsartan Hypertension FDA action 4Q14 Active Biotech AB (SSE:ACTI) / Ipsen Group (Euronext:IPN; Pink:IPSEY) Tasquinimod (TASQ...
BioCentury | Jul 14, 2014
Finance

3Q14 Financial Markets Preview: Summer lull

...in a hospital setting PDUFA date 7/27/14 Active Biotech AB (SSE:ACTI)/Ipsen Group (Euronext:IPN; Pink:IPSEY) Tasquinimod (TASQ...
Items per page:
1 - 10 of 51